[Anti-platelet aggregation effect of PGI2 potentiated by EG-626].
D000818:Animals; D003864:Depression, Chemical; D004357:Drug Synergism; D011464:Epoprostenol / Q000494:pharmacology*; D066298:In Vitro Techniques; D010208:Papaverine / Q000494:pharmacology; D010793:Phthalazines / Q000494:pharmacology*; D010974:Platelet Aggregation / Q000187:drug effects*; D011453:Prostaglandins / Q000494:pharmacology*; D011724:Pyridazines / Q000494:pharmacology*; D011817:Rabbits
D010793:Phthalazines; D011453:Prostaglandins; D011724:Pyridazines; C011329:phthalazinol; D010208:Papaverine; D011464:Epoprostenol